Genetic analysis of tumor samples by Next Generation Sequencing (NGS) from treatment resistant patients highlighted that several genetic alterations can contribute to therapy resistance and reduced patient survival e.g. KRAS, STK11, KEAP1 and the phosphatase and tensin homologue (PTEN) [12–14]. This evidence concerns the gene STK11 and neoplasm.